Peptides in Canada: Market Study and Growth System

Confidence tags: High = primary source we read (regulator, court, company filing, the seller's own page). Medium = reputable press or a survey. Low = vendor blog, single report or trade estimate. Estimate = our own arithmetic or judgment, inputs stated.

At a glance

The short version:

1. Demand is large and still climbing. Canadians filled close to 8 million Ozempic prescriptions in 2025. Search interest in "peptides" in the US now rivals "Ozempic", and Western Canada (BC, Alberta, Saskatchewan) over-indexes on peptides, BPC-157 and retatrutide. Medium
2. Canada is the first G7 country with generic semaglutide. Novo Nordisk's Canadian patent lapsed over an unpaid C$250 fee. Dr. Reddy's and Apotex were approved in April and May 2026, and the cash price fell by more than half in six months. High
3. There are four ways people make money from peptides in Canada today: research-peptide stores, GLP-1 telehealth, collagen and other natural health products, and peptide skincare. Each has a different price point, margin and marketing mix. Sections 2 and 3 cover them.
4. The stores that win are systems, not websites. Every serious player runs the same machine: content that captures search demand, reorder flows, bundles, affiliate codes, a community channel and fast shipping. That machine is what we build and automate (section 7).

1. The market

1.1 GLP-1 drugs: the one segment with hard numbers

What this means: the cash-pay pool, people paying themselves, is roughly 250,000 to 750,000 Canadians on GLP-1s today Estimate. That is the customer base every online GLP-1 business competes for.

1.2 The wider peptide market

• Global "peptide therapeutics" estimates range from about US$50B to about US$141B for 2025, depending on whether the publisher counts GLP-1s in full. Novo's semaglutide franchise (about US$33B) and Lilly's tirzepatide (US$39.5B in nine months of 2025) say the higher figure is closer. Low for the publishers, High for the company figures
• In US health records, newly documented BPC-157 users grew about 33x from Q1 2020 to Q1 2026. Users are 70% male with a mean age of 49. They source it 36% from compounding pharmacies and 35% from online vendors. Medium, preprint
• Analysts quoted by Reuters put BPC-157 and similar peptides at a possible US$2 to 3B market in the US if access widens. Low
• Google Trends, Canada: BC and Alberta lead the country on "peptides", "BPC-157" and "retatrutide". "Retatrutide canada" is a breakout rising query. High as a Trends read
• Biggest consumer search terms worldwide: "collagen peptides" first, "peptide serum" second, research compound names after. Low

1.3 What is driving demand

• Podcasts. Joe Rogan and Andrew Huberman's JRE #2553 includes a long segment on BPC-157, kisspeptin and GLP drugs. Peter Attia ran a full peptides episode in August 2026. Canadian stores already publish blog posts on these episodes within days. Medium
• US policy. On 28 October 2026 HHS published a draft policy that would let licensed US pharmacies compound six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax). Comments close 13 November. Five more go to an advisory meeting by February 2027. This raises awareness across North America. Medium
• Generic GLP-1s in Canada. Felix reported 14x weight-loss visit requests in the first 24 hours after generics launched. Medium

2. Who is selling, and how they make money

Model A: Research-peptide stores

Online stores that sell peptides by the vial with a research-use label, certificates of analysis and fast domestic shipping.

Source: each store's own pages, read 9 November 2026 High as prices.

How the money works:

• Finished vials are listed by factories at about US$30 per 10 mg vial (US$3 per mg). Canadian retail is C$150 to 250 for the same product, roughly 3.6x to 6x before freight, testing and fulfilment. Estimate on Low inputs
• Launch-service firms quote 60 to 80% gross margin and a US$180 (about C$250) average order. Low
• Bundles drive order size: Panda sells 5-packs at 10% off and 10-packs at 20% off, so a single order runs C$360 to 640. High
• First order math, at a C$250 order and 70% margin: about C$155 left after processing and fulfilment. Paid acquisition at US$60 to 180 per customer leaves roughly break-even on the first order. Creator or organic customers (under US$25) are profitable from order one. Estimate on Low inputs
• Profit comes from reorders. A 5 to 20 mg vial lasts about two to eight weeks on the sellers' own published tables, so the natural cycle is a monthly reorder. Estimate
• Scale marker: court documents put one US seller at more than 54,000 customers between 2019 and 2024. Low to Medium

Model B: GLP-1 telehealth

Online clinic plus partner pharmacy: the patient does an intake, a licensed prescriber approves, and the pharmacy ships.

How the money works:

• Drug cost about C$78 to 125 a pen; sale price C$125 to 149. Gross margin on the drug alone is 38 to 48%. Estimate
• Hims, the largest player, runs 64% blended gross margin and spends about 35% of revenue on marketing (Q2 2026). High
• About half of patients stop within a year. The money that lasts comes from add-on services: labs, nutrition, hormones, other conditions. Felix now covers 20+ categories. Medium

Model C: Collagen peptides and other natural health products

• Price anchor: Vital Proteins Collagen Peptides C$69.99 for 28 servings; Costco two-pack C$89.99. High list, Low Costco
• About 70% gross margin; US$45 to 80 to acquire a customer; 5 to 8% monthly churn. Low
• Retail-led category: Costco, Amazon and Shoppers set the price. DTC wins on a brand story, bundles and subscriptions.

Model D: Peptide skincare

• Price anchor: The Ordinary peptide serums at about US$11 to 32 for 30 mL. High
• About 69% gross margin; about US$60 to acquire a customer; about 30% repeat, reorder every ~104 days. Low
• Wins on a clinical or celebrity angle; without one, the mass brands set the price.

3. The research-peptide playbook: how the stores run

This is what the Canadian and US stores visibly do, from their sites and from press investigations.

Channel mix

What every serious store has

The gap we see Estimate: none of the four Canadian stores we read showed a subscription, loyalty program or automated reorder flow in their page text, and Helix North confirms payments by hand. The store that automates reorders, payment matching and community will out-retain the others.

4. Marketing: every channel

Every channel, what sellers in this market run on it, what the platform does, and what it costs. Three kinds of sellers show up in the data: research-peptide stores, telehealth and clinics, and skincare and collagen brands. Most per-channel numbers come from agencies that sell into this niche, so they carry a Low tag.

4.1 Channel by channel

4.2 Which channels carry the business

• Research-peptide stores: organic search, affiliate and creator codes, comparison sites, community channels and email carry the volume. Paid social and search are run as tests that come and go. Low, agency reports; no seller publishes traffic splits
• Telehealth: paid social, search and TV, plus creators paid per customer, then retention. Hims spends 39% of revenue on marketing and earns it back in 6 to 7 months. High
• Skincare and collagen: full use of every platform, creators and retail. Dietitians and dermatologists convert 2 to 3 times better than lifestyle creators for collagen. Low

4.3 Advertising rules in Canada that shape the creative

• Prescription drugs: ads to the public can show name, price and quantity only. Help-seeking ads can talk about the condition without naming the drug. High
• Obesity and diabetes: no ad to the public can present a drug as a treatment (Schedule A.1). High
• The service-led model: Eucalyptus grew its GLP-1 business in Australia, which has the same kind of ban, by advertising the service and the program instead of the drug. A$103M of marketing on about A$250M of revenue. Medium
• LegitScript certification (needed for telehealth ads on Meta, Google and Reddit): US$975 plus US$2,150 a year per site. It takes 2 weeks to 4 months, and Canadian businesses are eligible. High
• Influencer disclosure: Ad Standards' influencer guidelines require a clear #ad or paid-partnership label. The Competition Act holds the brand and the creator liable for undisclosed paid posts. High

4.4 The 90-day launch plan

4.5 If you have celebrity access

• Brand owner or creative chief: Jennifer Aniston has been Chief Creative Officer of Vital Proteins collagen peptides since 2020, alongside Nestle, which took a majority stake that year. Medium
• Paid creative: a scripted, licensed read in your ads, plus partnership ads that run from the celebrity's own handle.
• Podcast: host-read sponsorship on the shows that already talk about peptides.
• Contract: disclosure, approved claims, usage rights for paid media, exclusivity and term.

5. Operating in Canada: what to expect

How each product type is treated in Canada, what it needs, and what advertising can say. Checked against Health Canada's Prescription Drug List and Drug Product Database on 9 November 2026. High

Suppliers. A licensed Canadian supplier holds a Drug Establishment Licence or an NHP site licence, which covers its site and activities. Each product sold at retail carries its own DIN, NPN or cosmetic notification. You can check any product for free in Health Canada's Drug Product Database and Licensed Natural Health Products Database. High

Business structure for a GLP-1 lane. In BC a prescriber cannot own any part of a pharmacy. Alberta allows non-physician owners of clinics. In Ontario the practice corporation is restricted, so a management-services structure is used. Your lawyer sets this up. High for BC and Alberta, Medium for Ontario

What has happened to research-peptide stores in Canada, 2025 to 2026

• April 2026: Health Canada advisory listing BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, ipamorelin, KPV, melanotan, MOTS-c, SS-31, TB-500 and retatrutide. Health Canada is working with CBSA on inbound shipments. High
• Mid 2026: permanent Quebec Superior Court injunction against Canlab Research, after earlier injunctions in 2024 and 2025. High
• 6 November 2026:
  • Court entry warrants were executed against two web retailers, and both sites went offline. More than 11,400 vials have been seized in total.
  • Health Canada reported bacteria in seized product traced to one Shanghai supplier. High
• Earlier seizures: a Calgary wellness centre, Rize Fitness and two Maple Ridge stores. High
• Penalties in the Act:
  • Up to C$5M and 2 years per count, and each day counts separately.
  • Directors and officers can be personally liable.
  • No fine or conviction against a peptide seller has been found to date. The closest case is a C$1.07M fine in 2025 for an unauthorized prescription drug sold as "herbal". High
• What stores do (observed):
  • Canadian stores take Interac e-Transfer and crypto, and ship from domestic stock.
  • In the US, 19 of 23 stores that received a warning letter or lawsuit were still online in October 2026. Low to Medium

Other 2026 changes that affect operations

• Processors:
  • Helcim's policy (30 September 2026) excludes peptides that are not administered by a healthcare professional.
  • Moneris does not allow subscription billing for supplements or skincare.
  • Visa's dispute threshold for Canadian merchants dropped to 1.5% on 1 April 2026. High
  • Your merchants' own terms decide what runs where. The platform routes each product line to the right merchant.
• E-prescribing: PrescribeIT, Canada's e-prescribing network, closed on 29 May 2026. Prescriptions go to the pharmacy by secure fax or portal. High
• GLP-1 compounding: Health Canada treats compounding GLP-1s as manufacturing, so a GLP-1 lane runs on approved brand or generic product. High

6. Realistic potential

Three scenarios per model at month 12. These are our estimates. The inputs are stated so you can change them.

How we sized them Estimate:

• Model A: the US seller with 54,000 customers over five years averaged about 900 new customers a month. Canada has about one ninth of the US population. "Strong" assumes a top-three Canadian store with monthly reorders.
• Model B: if Felix's C$150M run rate were all GLP-1 at these prices, it would be about 60,000 paying patients a month. "Strong" is one tenth of that after a year.
• Models C and D: US DTC benchmarks, discounted because Costco, Amazon and the mass brands set the price.
• What moves a scenario up a column: a reorder rate above 40% a month, creator and organic customers at under C$35 each, and average order value lifted by bundles.

7. What we build for you

You run the business. We build the machine and the AI staff that keep it running, and you approve their work with one tap.

7.1 The platform

• Storefront:
  • Fast and built mobile-first.
  • A product page per compound with the certificate of analysis for each lot.
  • Stacks, multi-vial tiers and free-shipping threshold logic.
  • Reviews, guides, calculators and search.
• Checkout with your merchants: each product line routes to the merchant you choose, with hosted payment fields so card data never touches our servers. Interac e-Transfer requests are matched to orders automatically, with no manual checking, and crypto is optional.
• Back end and admin:
  • Orders and inventory by lot, with certificate-of-analysis storage.
  • Canada Post Xpresspost labels and tracking.
  • Refunds, plus a chargeback evidence pack built for every order.
• Reorders and loyalty: reminders timed to each product's cycle, one-click reorder, subscriptions where your merchant allows them, points and referral codes.
• Affiliate and creator system: codes and links for each creator, tracking, tiers, a payout ledger and a creator dashboard.
• Clinic module (optional, for a GLP-1 lane):
  • Intake and ID check.
  • Asynchronous prescriber review.
  • Handoff to the pharmacy.
  • Clinical records kept in a separate zone.

7.2 The AI staff (automation)

7.3 How it is built

• Next.js storefront and Postgres back end, hosted in Canada (AWS ca-central-1), with backups in a second Canadian region.
• Card data stays with your processors; we hold tokens only.
• Separate zones for shop data and, if you add a clinic, clinical data. Each has its own access, keys and audit log.

8. Customer data

How the system handles customer information:

• Hosting: Canadian hosting for all customer records. High that it is not legally required; we do it anyway
• Consent: a consent ledger records what each customer agreed to, the wording version and the timestamp. Email and SMS only go to people who opted in, as Canada's anti-spam law requires. High
• Customer rights: an access and deletion request workflow, a named privacy officer and a breach register. PIPEDA requires the breach register to be kept 24 months; Quebec requires 5 years. High
• Quebec: Quebec customers get Law 25 treatment: privacy impact assessments for new systems and for transfers outside Quebec, plus a notice to the regulator if selfie ID checks are used. High
• Retention: a retention schedule for each record type, with scheduled deletion and a deletion log.
• Minimal data: card data never touches our servers. ID images stay with the verification vendor, and we keep only pass or fail.
• Coming law: Bill C-36, the federal privacy bill introduced June 2026, is not law yet. The system is built so its expected rules (health data treated as sensitive, cross-border assessments) need no rebuild. High on status

9. Timeline and investment

Sources

Market and prices

• IQVIA Canada, Top 20 dispensed drugs 2025: https://www.iqvia.com/-/media/iqvia/pdfs/canada/2025-trends/english/top20dispensed_25.pdf
• Globe and Mail on GLP-1 sales (IQVIA data): https://www.theglobeandmail.com/business/article-glp-1-weight-loss-on-ozempic-wegovy-canada/
• Leger survey via CBC, Feb 2026: https://www.cbc.ca/news/health/canadians-glp1-ozempic-mounjaro-9.7114197
• Generic semaglutide approval and patent lapse: https://www.drugdiscoverytrends.com/canada-approves-generic-semaglutide-from-dr-reddys-a-g7-first-enabled-by-novo-nordisks-lapsed-cad250-patent/
• GLP-1 price comparison, Canada: https://glp1prices.ca/compare and https://glp1prices.ca/online-glp1-prescription-canada
• Maple on semaglutide cost: https://www.getmaple.ca/blog/semaglutide-ozempic-cost-in-canada/
• Felix pricing: https://www.felixforyou.ca/pricing/
• Hims & Hers Q2 2026 results: https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Second-Quarter-2026-Financial-Results/default.aspx
• GLP-1 persistence, American Academy of Actuaries, Sep 2026: https://actuary.org/wp-content/uploads/2026/09/GLP1.PolPap.9.26-1.pdf
• DTC supplement benchmarks: https://foundrycro.com/blog/dtc-supplements-marketing-benchmarks-2026/

Demand

• BPC-157 use up 33x (nference preprint): https://www.ajmc.com/view/bpc-157-wolverine-peptide-use-rose-33-fold-despite-scant-evidence
• Reuters via CTV on peptide demand: https://www.ctvnews.ca/health/article/use-of-untested-wolverine-peptide-on-the-rise-study-finds/
• Google Trends, Canada: https://trends.google.com/trends/explore?geo=CA&q=peptides,BPC-157,retatrutide,semaglutide&date=today%205-y
• US peptide policy, Holland & Knight: https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know
• HHS draft policy, CBS News: https://www.cbsnews.com/news/rfk-jr-to-ease-access-unapproved-peptides-draft-policy/

Research-peptide stores and playbook

• Panda Peptide: https://pandapeptide.ca/buy-peptides-canada/
• Polar Peptides: https://polarpeptides.ca/products/bpc-157/
• Advance Peptides: https://advpeptides.ca/complete-guide-to-peptides-canada-2026/
• Helix North: https://helixnorth.ca/canadian-research-peptides
• The Guardian on creator codes and Telegram: https://www.theguardian.com/money/2025/oct/11/tiktok-influencers-telegram-whatsapp-parallel-market-unlicensed-weight-loss-drug-retatrutide-uk
• WBUR/WUSF on factory-direct buying: https://www.wusf.org/2026-03-24/people-are-buying-unregulated-injectable-peptides-from-chinese-factories-are-they-safe
• Survey of 93 storefronts: https://dadstrengthdaily.com/research-use-only-peptide-stores/
• Launch economics: https://peptide.business/blog/peptide-business-cost and https://peptblueprint.com/blog/how-to-start-a-peptide-business
• Peptide SEO data: https://www.lanternsol.com/blog/peptide-seo-playbook

Canada rules and enforcement

• Food and Drugs Act: https://laws-lois.justice.gc.ca/eng/acts/F-27/FullText.html
• Health Canada peptides pages: https://www.canada.ca/en/health-canada/services/drugs-health-products/peptides/research-clinical-trials.html
• Health Canada advisory, 9 Apr 2026: https://recalls-rappels.canada.ca/en/alert-recall/think-twice-injecting-peptides-bought-online-unauthorized-products-can-seriously-harm
• Health Canada advisory, 6 Nov 2026: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-warns-about-contaminated-unauthorized-injectable-peptides-and-non
• Canlab injunction: https://www.smartbiggar.ca/insights/publication/health-canada-obtains-permanent-injunction-to-prevent-illegal-sale-of-injectable-peptides-by-canlab-research

Marketing

• Meta Ad Library tracker, Felix Health: https://admanage.ai/ad-library/felix-health
• Google unapproved substances policy: https://support.google.com/adspolicy/answer/15595718?hl=en
• TikTok Shop health content rules: https://seller-us.tiktok.com/university/essay?knowledge_id=4545471832983342&lang=en
• Taboola restricted content: https://www.taboola.com/help/en/articles/3878199-restricted-content-products-and-services
• Klaviyo acceptable use policy: https://www.klaviyo.com/legal/acceptable-use-policy
• Health podcast CPM benchmarks: https://www.podderapp.com/post/health-podcast-cpm-benchmarks
• Huberman Lab peptide episode and sponsors: https://www.hubermanlab.com/episode/peptides-the-science-uses-and-safety-abud-bakri
• Peptide affiliate program comparison: https://validatedpeptides.com/research/best-peptide-affiliate-program
• eMarketer on influencer-driven peptide demand: https://www.emarketer.com/content/peptide-buzz-climbs-influencer-hype-drives-demand-online
• Peptide ad channels (agency guide): https://advancemedia.com/the-definitive-guide-to-best-places-to-advertise-for-peptides-online/
• Store marketing case study (Paragon): https://thestudiocreative.com/post/peptide-company-marketing-case-study-paragon
• Healthcare affiliate performance: https://impact.com/affiliate/affiliate-healthcare-performance-marketing/